ImmunityBio (IBRX)
NASDAQ:IBRX
$13.41
-$0.49(-3.53%)
IBRXImmunityBio
$13.41
-$0.49 (-3.53%)

ImmunityBio Stock Analysis & Ratings

ImmunityBio Stock Analysis Overview

Smart Score
5
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The ImmunityBio stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, Data-Driven rating system and does not include human intervention.

Stock Chart

IBRX
$13.41
-$0.49 (-3.53%)

IBRX Stock Stats

Previous Close$13.9
Open$13.72
Bid0 x 0
Ask0 x 0
Today’s Range$12.71 - $13.8468
52-Week Range$6.03 - $45.42
Volume7.19M
Average Volume1.39M
Market Cap$5.15B
Beta2.13
P/E Ratio-63.9
EPS-0.21

Company Description

ImmunityBio

NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The firm operates through the following geographical segments: United States; Europe; and Other Non-U.S. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard Adcock
Employees
N/A
Address
3530 John Hopkins Court, San Diego, CA, 92121, US

Financials

Currently, no data available
Please return soon as the page is updated accordingly.

P/E Ratio Range

Currently, no data available
Please return soon as the page is updated accordingly.
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

IBRX FAQ

What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $6.03 and its highest was $45.42 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $5.15B.
What is ImmunityBio’s price target?
The average price target for ImmunityBio is $25.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $25.00. The average price target represents 86.43% Increase from the current price of $13.41.
What do analysts say about ImmunityBio?
ImmunityBio’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
When is ImmunityBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImmunityBio’s earnings last quarter?
Currently, no data Available
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 383,910,000 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ImmunityBio?
Among the largest hedge funds holding ImmunityBio’s share is Gotham Asset Management LLC. It holds ImmunityBio’s shares valued at N/A.

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis